TUMOR EVOLUTION AND GENOMIC HETEROGENEITY

With the understanding of tumor evolution and genomic heterogeneity, researchers may develop effective cancer therapies. Intra-tumor heterogeneity, which refers to the presence of different genetic and epigenetic subpopulations within a tumor, promotes tumor evolution and presents a significant challenge in cancer treatment (Table 2).

Genomic instability, a major cause of genetic heterogeneity in cancer, increases the mutation rate and influences the evolution of the cancer genome (Fig. 3) [40]. Tumor subclones, exhibiting differential gene expression due to genetic and epigenetic heterogeneity, contribute to the complexity of tumor evolution [41]. Cancer cells continuously adapt to their surrounding environment, allowing them to resist treatment and suppress the human immune system's ability to recognize and eliminate these cells. In distinct forms of cancer, which vary in their genetic and epigenetic heterogeneity, a similar evolutionary pattern emerges for a given tumor. The interaction between genetic and epigenetic factors results in complex tumor evolution, affecting the treatment response as well as disease progression [42]. To develop targeted and personalized treatment approaches, a thorough understanding of the evolutionary dynamics of genetic heterogeneity is essential [43]. By unraveling the evolutionary dynamics of tumors, researchers have focused on developing targeted therapies that account for the diverse genetic and epigenetic profiles of individual tumors. Such personalized approaches hold promise for enhancing the treatment outcomes of cancer patients. However, tumor evolution and genomic heterogeneity are complex processes that significantly impact cancer progression and treatment. The evolutionary dynamics of cancer cells, driven by genetics (dysregulation of oncogenes and tumor suppressor gene) and environmental factors, underscore the complexity of tumor evolution [44]. This deeper understanding of tumor evolution holds the potential to transform the landscape of cancer care, offering new hope for improved patient outcomes and survival rates.